These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20217604)

  • 1. Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.
    Rothdiener M; Beuttler J; Messerschmidt SK; Kontermann RE
    Methods Mol Biol; 2010; 624():295-308. PubMed ID: 20217604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of nanoparticles: folate receptor.
    Kularatne SA; Low PS
    Methods Mol Biol; 2010; 624():249-65. PubMed ID: 20217601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel single-chain Fv' formats for the generation of immunoliposomes by site-directed coupling.
    Messerschmidt SK; Kolbe A; Müller D; Knoll M; Pleiss J; Kontermann RE
    Bioconjug Chem; 2008 Jan; 19(1):362-9. PubMed ID: 17988079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.
    Lu RM; Chang YL; Chen MS; Wu HC
    Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building and characterizing antibody-targeted lipidic nanotherapeutics.
    Kirpotin DB; Noble CO; Hayes ME; Huang Z; Kornaga T; Zhou Y; Nielsen UB; Marks JD; Drummond DC
    Methods Enzymol; 2012; 502():139-66. PubMed ID: 22208985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
    Simard P; Leroux JC
    Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.
    Dinauer N; Balthasar S; Weber C; Kreuter J; Langer K; von Briesen H
    Biomaterials; 2005 Oct; 26(29):5898-906. PubMed ID: 15949555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.
    Schnyder A; Krähenbühl S; Török M; Drewe J; Huwyler J
    Biochem J; 2004 Jan; 377(Pt 1):61-7. PubMed ID: 14516278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D; Garg A; Kokkoli E
    Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells.
    Messerschmidt SK; Musyanovych A; Altvater M; Scheurich P; Pfizenmaier K; Landfester K; Kontermann RE
    J Control Release; 2009 Jul; 137(1):69-77. PubMed ID: 19306900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
    Rüger R; Tansi FL; Rabenhold M; Steiniger F; Kontermann RE; Fahr A; Hilger I
    J Control Release; 2014 Jul; 186():1-10. PubMed ID: 24810115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
    McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
    Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.
    Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR
    Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system.
    Kakudo T; Chaki S; Futaki S; Nakase I; Akaji K; Kawakami T; Maruyama K; Kamiya H; Harashima H
    Biochemistry; 2004 May; 43(19):5618-28. PubMed ID: 15134436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.